NovaBay Pharmaceuticals Accepts Revised Offer
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) has recently announced a notable shift in its strategic direction, accepting a revised offer from PRN Physician Recommended Nutriceuticals, LLC. This new proposal significantly enhances the purchase price for NovaBay's eyecare division, increasing it from $9.5 million to $11.5 million. This amendment reflects the company's commitment to maximizing value for its stakeholders amid changing market conditions.
Amendment to the Asset Purchase Agreement
The amended agreement, known as the PRN Asset Purchase Agreement, introduces several favorable terms. Notably, it removes debt financing contingencies, ensuring that PRN has the necessary funds available for this transaction. The agreement also includes a secured promissory note from PRN for $1 million, structured to be paid in two installments. This Bridge Loan is designed to bolster stability for the acquisition process.
CEO's Statement on the Revised Offer
Justin Hall, the CEO of NovaBay, expressed optimism regarding the revised offer. He stated, "We are thrilled to accept PRN's revised offer for the Avenova brand. The additional value solidifies our belief that this deal serves the best interests of our stockholders." Such statements from leadership indicate a proactive approach in navigating the complexities of the deal-making process.
Evaluation of Competing Proposals
In considering the new offer, NovaBay's Board of Directors undertook a thorough assessment of alternative proposals, including an unsolicited offer from Refresh Acquisitions BidCo LLC. What may have initially appeared to be a superior proposal was ultimately deemed less favorable than the revised terms presented by PRN. This careful evaluation underscores the Board's dedication to acting in the shareholders' best interests.
Upcoming Special Meeting
Looking ahead, the company has scheduled a Special Meeting of stockholders for further deliberation on this transaction. This meeting, set for an upcoming date, is crucial as it seeks formal approval of the amendments and the overall sale process. NovaBay remains committed to transparency, encouraging stockholders to reach out for assistance in understanding the voting process.
Recommendations and Future Steps
The Board unanimously continues to recommend that stockholders approve the transaction with PRN, along with the potential voluntary liquidation of the Company. This dual recommendation signals a strategic exit plan while maximizing value through the ongoing deal with PRN.
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals is renowned for its leading product, Avenova Lid & Lash Cleansing Spray, which is particularly effective for treating blepharitis and dry eye disease. The spray is manufactured in the United States using a patented and stable form of hypochlorous acid, setting it apart in the market. Consumers can conveniently access Avenova products through online platforms, making it easier to obtain this essential eyecare solution.
Frequently Asked Questions
What is the revised offer from PRN?
The revised offer from PRN increases the purchase price for NovaBay's eyecare business from $9.5 million to $11.5 million.
What does the Amendment entail?
The Amendment to the Asset Purchase Agreement removes debt financing contingencies, adds a secured promissory note, and confirms PRN's funding for the purchase.
How is NovaBay's Board involved in the decision?
The Board conducted a thorough assessment of the proposal from PRN, considering other offers before concluding that the PRN deal is in the best interest of stockholders.
When will the Special Meeting take place?
The Special Meeting of stockholders is scheduled to discuss and approve the transaction with PRN, though the specific date is forthcoming.
What are the benefits of Avenova products?
Avenova products are recommended for treating common eyelid issues, providing a safe and effective solution that is accessible online.
